Text Size

A Study of the Antioxidant Probucol Combined With Valsartan in Patients With IgA Nephropathy

This study is ongoing, but not recruiting participants.
Sponsor:
Information provided by (Responsible Party):
Wei Shi, Guangdong General Hospital
ClinicalTrials.gov Identifier:
NCT00426348
First received: January 23, 2007
Last updated: January 6, 2012
Last verified: January 2012
History of Changes
  Purpose

a statement of the study hypothesis:the effect of valsartan in patients with IgA nephropathy have been proved,and the efficacy of probucol in combination with valsartan is to be proved in patients with IgA nephropathy.

This is a prospective randomized controlled, double blinded pilot study to identify the efficacy of probucol in combination with valsartan in patients with IgA nephropathy. The renal function deterioration will be the primary outcome studied. The expected study duration will be 36 months.


Condition Intervention Phase
Glomerulonephritis
IGA Nephropathy
 Drug: Valsartan
Drug: Probucol
Drug: Placebo
 Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Prospective Randomized, Controlled, Double Blinded Trial of the Antioxidant Probucol Combined With Valsartan in Patients With IgA Nephropathy

Resource links provided by NLM:

MedlinePlus related topics: Antioxidants
Drug Information available for: Valsartan
U.S. FDA Resources

Further study details as provided by Guangdong General Hospital:

Primary Outcome Measures:
  • urinary protein loss whithin 24 hours [ Time Frame: 2-3years ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • renal function(serum Crea or eGFR) deterioration [ Time Frame: 2-3years ] [ Designated as safety issue: No ]

Estimated Enrollment: 120
Study Start Date: May 2007
Estimated Study Completion Date: December 2012
Estimated Primary Completion Date: May 2012 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: 1
In arm 1,Valsartan(80-160mg/day) is given to patients in combination with Placebo
 Drug: Valsartan
Valsartan (80-160mg/day)
Other Name: Valsartan
Drug: Placebo
Placebo
Experimental: 2
Valsartan(80-160mg/day) + Probucol(750mg/day)
 Drug: Valsartan
Valsartan (80-160mg/day)
Other Name: Valsartan
Drug: Probucol
Probucol (750mg/day)

  Eligibility

Ages Eligible for Study:   18 Years to 60 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Patients who fulfill the clinical and pathological criteria for IgA nephropathy
  • Age: 18-60 years
  • Renal biopsy diagnostic for IgA nephropathy based on immunohistologic staining for IgA that is greater than or equal to staining for IgG and IgM
  • Urinary protein excretion rate is within the range of 1-2.5g/day
  • Serum creatinine <265.2umol/L at the time of randomization

Exclusion Criteria:

  • Patients who refuse to be randomized for treatment
  • Patients who prefer treatment with conventional agents
  • Patients who are pregnant or plan for pregnancy
  • Patients who are pathologically proven severely or diffusely proliferative IgA nephropathy or crescent glomerulonephritis with >= 50% segmental involvement of the glomeruli and should be treated with other agents,such as immunosuppressive agents or steroid

  • Clinical and histologic evidence of:

    • systemic lupus erythematosus
    • Henoch-Schonlein purpura
    • cirrhosis
    • chronic active liver disease
    • hepatitis B
    • hepatitis C
    • severe chronic diarrhea
    • active peptic ulcer disease
    • HIV
    • acute renal failure
    • malignant hypertension
    • severe heart diseases
    • malignant tumor
    • any systemic infection
    • pregnancy
    • Known contraindication to the administration of probucol and valsartan
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00426348

Locations
China, Guangdong
Guangdong General Hospital
Guangzhou, Guangdong, China, 510080
Sponsors and Collaborators
Guangdong General Hospital
Investigators
Principal Investigator: Wei Shi, PhD,MD Nephrology Dept.,Guangdong General Hospital
  More Information

No publications provided

Responsible Party: Wei Shi, Director of renal division of Guangdong General Hospital, Guangdong General Hospital
ClinicalTrials.gov Identifier: NCT00426348     History of Changes
Other Study ID Numbers: GPPH200603
Study First Received: January 23, 2007
Last Updated: January 6, 2012
Health Authority: China: Ethics Committee

Keywords provided by Guangdong General Hospital:
IgA nephropathy
probucol
valsartan
 treatment
antioxidant
IGA nephropathy：a kind of glomerulonephritis,which IgA is the dominant immunodeposit in mesangial areas

Additional relevant MeSH terms:
Glomerulonephritis
Glomerulonephritis, IGA
Kidney Diseases
Nephritis
Urologic Diseases
Autoimmune Diseases
Immune System Diseases
Antioxidants
Probucol
Valsartan
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
 Protective Agents
Physiological Effects of Drugs
Anticholesteremic Agents
Hypolipidemic Agents
Antimetabolites
Lipid Regulating Agents
Therapeutic Uses
Angiotensin II Type 1 Receptor Blockers
Angiotensin Receptor Antagonists
Antihypertensive Agents
Cardiovascular Agents

ClinicalTrials.gov processed this record on May 21, 2013